Arvinas to Present at Upcoming Investor Conferences
February 03, 2022 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
January 10, 2022 06:30 ET
|
Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
December 10, 2021 08:10 ET
|
Arvinas Inc.
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is...
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 19, 2021 09:55 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
November 10, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 03, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
July 22, 2021 07:00 ET
|
Arvinas Inc.
– Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast oncology therapeutics – – ARV-471 is currently in Phase 2...
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
June 07, 2021 17:19 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 03, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...